X4 Pharmaceuticals, Inc.
XFOR
$0.2023
-$0.0077-3.67%
| Weiss Ratings | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.14 | |||
| Price History | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -24.91% | |||
| 30-Day Total Return | -56.69% | |||
| 60-Day Total Return | -71.18% | |||
| 90-Day Total Return | -45.09% | |||
| Year to Date Total Return | -73.10% | |||
| 1-Year Total Return | -86.24% | |||
| 2-Year Total Return | -75.63% | |||
| 3-Year Total Return | -89.41% | |||
| 5-Year Total Return | -97.75% | |||
| 52-Week High % Change | -86.36% | |||
| 52-Week Low % Change | 5.00% | |||
| Price | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.54 | |||
| 52-Week Low Price | $0.20 | |||
| 52-Week Low Price (Date) | Apr 03, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 36.47M | |||
| Enterprise Value | 12.50M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.19 | |||
| Earnings Per Share Growth | -68.88% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 16.67 | |||
| Price/Book (Q) | 1.62 | |||
| Enterprise Value/Revenue (TTM) | 4.89 | |||
| Price | $0.20 | |||
| Enterprise Value/EBITDA (TTM) | -0.09 | |||
| Enterprise Value/EBIT | -0.09 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 202.93M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 529 8300 | |||
| Address | 61 North Beacon Street Boston, MA 02134 | |||
| Website | www.x4pharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -5,529.95% | |||
| Profit Margin | -1,464.60% | |||
| Management Effectiveness | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -60.18% | |||
| Return on Equity | -- | |||
| Income Statement | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.56M | |||
| Total Revenue (TTM) | 2.56M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 1.76M | |||
| EBITDA (TTM) | -140.61M | |||
| EBIT (TTM) | -141.40M | |||
| Net Income (TTM) | -37.45M | |||
| Net Income Avl. to Common (TTM) | -37.45M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -108.16% | |||
| EPS Diluted (TTM) | -0.19 | |||
| EPS Diluted Growth (Q YOY) | -103.11% | |||
| Balance Sheet | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 102.06M | |||
| Cash Per Share (Q) | $0.50 | |||
| Total Current Assets (Q) | 112.18M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 22.15M | |||
| Current Ratio (Q) | 3.412 | |||
| Book Value Per Share (Q) | $0.13 | |||
| Total Assets (Q) | 146.45M | |||
| Total Current Liabilities (Q) | 32.88M | |||
| Total Debt (Q) | 78.09M | |||
| Total Liabilities (Q) | 124.30M | |||
| Total Common Equity (Q) | 22.15M | |||
| Cash Flow | XFOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 66.99M | |||
| Cash from Financing (TTM) | 20.29M | |||
| Net Change in Cash (TTM) | -43.77M | |||
| Levered Free Cash Flow (TTM) | -83.72M | |||
| Cash from Operations (TTM) | -130.90M | |||
